Table 2 Adverse events experienced by patients on rupatadine 40 mg and placebo.
From: A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection
Rupatadine 40 mg N = 66 | Placebo N = 67 | P value | |
|---|---|---|---|
Abdominal pain (%) | 17 (25.7) | 21 (31.3) | 0.5 |
Vomiting (%) | 21 (31.8) | 21 (31.3) | 1.0 |
Diarrhoea (%) | 27 (40.9) | 24 (35.8) | 0.7 |
Hepatitis (%) (ALT > 250/L) | 3 (4.5) | 6 (8.9) | 0.3 |
Low platelet counts | |||
<20 × 109/L (%) | 12 (18.2) | 14 (20.9) | 0.8 |
20 to 50 × 109/L (%) | 17 (25.7) | 21 (31.3) | 0.2 |
High ALT (>200 U/L) (%) | 9 (13.6) | 12 (17.9) | 0.2 |
High AST (>200 U/L) (%) | 14 (21.2) | 18 (26.9) | 0.6 |
Low white cell count (<1 × 109/L) (%) | 0 (0) | 0 (0) | 1.00 |
